Personalized Diagnostics, Treatment, and Outcomes of Chronic Kidney Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1019

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Interests: chronic kidney disease; hypertension; diabetes mellitus
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic kidney disease is one of the most potent risk factors for end-stage kidney disease. The number of patients with chronic kidney disease is increasing. Although several new drugs have been launched in clinical practice, the global need for optimal strategies to prevent the progression of chronic kidney disease urgently needs to be addressed. This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of the science and present the latest findings in the field of chronic kidney disease. We call for research that explores all conditions associated with chronic kidney disease, using basic science, clinical- and population-based approaches, and all kinds of actions for public awareness. Scientific advancements in the field of chronic kidney disease promise a brighter future for patients.

Prof. Dr. Haruhito A. Uchida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic kidney disease
  • clinical research
  • basic research
  • epidemiology
  • prevention
  • public awareness

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 260 KiB  
Article
The Impact of Chronic Kidney Disease on the Mortality Rates of Patients with Urological Cancers—An Analysis of a Uro-Oncology Database from Eastern Europe
by Mircea Ciorcan, Șerban Negru, Răzvan Bardan, Alin Cumpănaș, Iasmina Mattar, Yahya Bitar, Lazăr Chișavu, Luciana Marc, Adalbert Schiller and Adelina Mihăescu
J. Pers. Med. 2023, 13(11), 1572; https://doi.org/10.3390/jpm13111572 - 3 Nov 2023
Viewed by 824
Abstract
(1) Background: The relationship between chronic kidney disease (CKD) and urological cancers is complex, as most of these cancers are diagnosed in patients with advanced ages, when the kidney function may be already impaired. On the other hand, urological cancers could represent a [...] Read more.
(1) Background: The relationship between chronic kidney disease (CKD) and urological cancers is complex, as most of these cancers are diagnosed in patients with advanced ages, when the kidney function may be already impaired. On the other hand, urological cancers could represent a risk factor for CKD, significantly reducing the life expectancy of the patients. The main objective of our study was to analyze the impact of CKD on the overall mortality of patients diagnosed with the most frequent types of urological cancers. (2) Material and Methods: We conducted an observational retrospective cohort study on a group of 5831 consecutive newly diagnosed cancer patients, followed over a 2-year period (2019–2020), from a large Oncology Hospital in Romania. From this group, we selected only the patients diagnosed with urological malignancies, focusing on prostate cancer, bladder cancer and renal cancer; finally, 249 patients were included in our analysis. (3) Results: In the group of patients with prostate cancer (n = 146), the 2-year overall mortality was 62.5% for patients with CKD, compared with 39.3% for those with no initial CKD (p < 0.05). In the group of patients with bladder cancer (n = 62), the 2-year overall mortality was 80% for patients with initial CKD, compared with 45.2% for the patients with no initial CKD (p < 0.05). Finally, in the group of patients with renal cell carcinoma (n = 41), the 2-year overall mortality was 60% for patients with initial CKD, compared with 50% for the patient group with no initial CKD (p < 0.05). Various correlations between specific oncologic and nephrological parameters were also analyzed. (4) Conclusions: The presence of CKD at the moment of the urological cancer diagnosis is associated with significantly higher 2-year mortality rates. Full article
Back to TopTop